Biogen Stock News

Biogen investors are eagerly awaiting guidance about whether and how Medicare will cover the drugmaker's Alzheimer's disease therapy, Aduhelm.

Biogen investors are eagerly awaiting guidance about whether and how Medicare will cover the drugmaker's Alzheimer's disease therapy, Aduhelm.

Biogen investors are eagerly awaiting guidance about whether and how Medicare will cover the drugmaker's Alzheimer's disease therapy, Aduhelm.

In this battle of biotech giants, one emerges as the clear winner.

Biogen Inc. (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Biogen (BIIB) exercises its option to acquire a royalty-bearing license from Ionis to develop and commercialize BIIB115/ION306 for treating spinal muscular atrophy.

The Alzheimer's Disease treatment market is known for its vast potential given the fact that there are hardly any active drugs and therapies that produce any real improvements in patients' conditions.

Dublin, Jan. 05, 2022 (GLOBE NEWSWIRE) -- The "Central Nervous Disorders Therapeutics Market by Disease, Distribution Channel, and Age Group: Global Opportunity Analysis and Industry Forecast, 2021-2030" report has been added to ResearchAndMarkets.com''s offering. The central nervous disorders therapeutics market generated $1,17,556.10 million in 2020 and is projected to reach $2,32,294.20 million by 2030, growing at a CAGR of 7.3% from 2021 to 2030. The central nervous system (CNS) is a complex system that regulates and coordinates body activities. Central nervous system (CNS) disorders, also known as central nervous system diseases. It is a group of neurological disorders that affect structure and function of brain and spinal cord. The group of disorder including tumors that cause delayed puberty. However, CNS disorders such as neurodegenerative diseases, Alzheimer''s disease, Parkinson''s disease, multiple sclerosis, autoimmune & inflammatory diseases, genetic disorders, cancers, and others affect structure and function of the brain or spinal cord.

Early results were so impressive the company raced toward regulatory approval. But its decision to stop trials produced a therapy without proven efficacy that many patients arent taking; potentially the worst drug launch of all time.

Early results were so impressive the company raced toward regulatory approval. But its decision to stop trials produced a therapy without proven efficacy that many patients arent taking; potentially the worst drug launch of all time.

Alzheimer''s treatment maker could be poised for short-term rebound as takeover talk surfaces.

Biogen''s Alzheimer''s drug Aduhelm was heralded as a historic triumph against the memory-robbing disease. Now, the company is trying to keep it afloat.

(RTTNews) - Biogen Inc. (BIIB) and Ionis Pharmaceuticals, Inc. (IONS) said Biogen exercised its option to obtain from Ionis a worldwide, royalty-bearing license to develop and commercialize BIIB115/ION306, a preclinical investigational antisense oligonucleotide in development for spinal muscular atrophy. As a part of the option exercise, Biogen